Rockefeller Capital Management L.P. Galectin Therapeutics Inc Transaction History

Rockefeller Capital Management L.P.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$1.61 - $2.31 $6,440 - $9,240	-4,000 Reduced 31.04%	8,886 $14,000
Q3 2021 Nov 12, 2021	BUY	$2.59 - $4.15 $6,475 - $10,375	2,500 Added 24.07%	12,886 $49,000
Q2 2021 Aug 10, 2021	BUY	$2.07 - $5.1 $17,359 - $42,768	8,386 Added 419.3%	10,386 $33,000
Q4 2019 Feb 07, 2020	BUY	$2.79 - $4.32 $5,580 - $8,640	2,000 New	2,000 $6,000

9.69M

1.16M

1.98M

Ticker GALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,426,000
Market Cap $73.7M
Description
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...

Get notified when there are updates to the investment portfolio of Rockefeller Capital Management L.P., based on Form 13F filings with the SEC.

Stay updated on Rockefeller Capital Management L.P. with notifications on news.